DARZALEX FASPRO® demonstrated efficacy consistent with DARZALEX®
In the COLUMBA trial, the co-primary endpoint was achieved:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) was non-inferior to
DARZALEX® (daratumumab) with regard to overall response rate (ORR).1
*DARZALEX FASPRO® (95% CI: 35, 47).
†DARZALEX® (95% CI: 31, 43).
The co-primary endpoint of remaining therapeutic drug concentration (maximum Ctrough) of DARZALEX FASPRO® was also non-inferior to DARZALEX®.1
CI=confidence interval; CR=complete response; Ctrough=trough concentration; ORR=overall response rate; PR=partial response; VGPR=very good partial response.